First‐Time‐in‐Human Study With GSK249320, a Myelin‐Associated Glycoprotein Inhibitor, in Healthy Volunteers

@article{Abila2013FirstTimeinHumanSW,
  title={First‐Time‐in‐Human Study With GSK249320, a Myelin‐Associated Glycoprotein Inhibitor, in Healthy Volunteers},
  author={B. Abila and E. Cunningham and M. Simeoni},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2013},
  volume={93}
}
GSK249320, a monoclonal antibody directed against myelin‐associated glycoprotein (MAG), is being developed for the enhancement of recovery of function poststroke. Potential safety concerns of adverse effects on myelin led to the inclusion of pharmacodynamic measures of peripheral and central neuronal function in this first‐time‐in‐human (FTIH) study. The study also evaluated general safety, pharmacokinetics, and immunogenicity of GSK249320. Single intravenous infusions of GSK249320 (0.04, 0.4… Expand
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke
TLDR
Modality-specific end points could be consistently measured in the first few days after stroke, and one of these, gait velocity, demonstrated a trend toward improvement with GSK249320 compared with placebo, suggesting that this first study of a monoclonal antibody to modulate the neurobiology of brain repair after stroke was generally well tolerated. Expand
Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients
TLDR
GSK249320, within 72 hours of stroke, demonstrated no improvement on gait velocity compared with placebo, findings potentially useful to future studies aiming to use a monoclonal antibody to modify activity in specific biological pathways to improve recovery from stroke. Expand
Safety , Pharmacokinetics , and Pharmacodynamics of Escalating Repeat Doses of GSK 249320 in Patients With Stroke
Rationale: Myelin-associated glycoprotein (MAG) is one of the key proteins known to inhibit neuronal regeneration when released from oligodendrocytes in conditions of neuronal injury, such as stroke.Expand
Effects of Postinfarct Myelin-Associated Glycoprotein Antibody Treatment on Motor Recovery and Motor Map Plasticity in Squirrel Monkeys
TLDR
Results suggest that GSK249320 has a substantial biological effect on spared cortical tissue, however, its mechanisms of action may be widespread and not strictly limited to peri-infarct cortex and nearby premotor areas. Expand
Monoclonal antibody as an emerging therapy for acute ischemic stroke.
TLDR
This review will focus on recent advances on AIS therapy by using mAb that targets the signaling cascades and endogenous molecules such as inflammation, growth factors, acid-sensing ion channels, and N-methyl-D-aspartate receptors. Expand
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013
TLDR
The MABEL-based approach appears to be safer and as efficient as the other MRSD determination methods for achieving the objectives of FIH studies with mAbs faster. Expand
The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats.
TLDR
The role of the lymphatic system in the absorption and prolonged plasma exposure of trastuzumab was explored and an extensive direct absorption from the SC injection site into lymph may enable novel therapeutic strategies for the treatment of lymph resident metastatic cancer. Expand
Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research
Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size. The mainExpand
Blocking the Nogo-A Signaling Pathway to Promote Regeneration and Plasticity After Spinal Cord Injury and Stroke
TLDR
Current experimental CNS repair strategies and clinical trials that use reagents which neutralize Nogo-A or suppress Nogo signaling, in particular for spinal cord injury and stroke are summarized, with some results also in amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Expand
Adequate Platelet Function Inhibition Confirmed by Two Inductive Agents Predicts Lower Recurrence of Ischemic Stroke/Transient Ischemic Attack
TLDR
The platelet function tested by PL-11 demonstrated that adequate inhibition of both MARADP and MARAA could predict lower risk of ischemic stroke/TIA recurrence. Expand
...
1
2
...

References

SHOWING 1-10 OF 32 REFERENCES
Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development
TLDR
This review provides an overview of the molecular, biochemical, and pharmacokinetic properties and clinical development history of Mabs and details how these factors currently affect the scope and design of early clinical development strategies for these drug candidates. Expand
Identification of Neuroprotective Properties of Anti-MAG Antibody: A Novel Approach for the Treatment of Stroke?
  • E. Irving, M. Vinson, +9 authors A. A. Parsons
  • Medicine
  • Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2005
TLDR
The novel finding that an anti-MAG monoclonal antibody not only possesses the ability to neutralise the inhibitory effect of MAG on neurons but also directly protects oligodendrocytes from glutamate-mediated oxidative stress-induced cell death is reported here. Expand
Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS
TLDR
The data support the prognostic value of anti-myelin antibodies in CIS patients at risk of CDMS, with positive patients showing shorter time interval to relapse occurrence than negative patients. Expand
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.
TLDR
Analysis of antibodies against MOG and MBP in patients with a clinically isolated syndrome is a rapid, inexpensive, and precise method for the prediction of early conversion to clinically definite multiple sclerosis. Expand
Anti–myelin‐associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia
TLDR
The presence of low levels of anti‐MAG IgM in a significant proportion of controls suggests that monoclonal expansion of naturally occurring B‐cell clones secreting anti‐ MAG IgM may be responsible for the high incidence of this antigen specificity of the M‐protein. Expand
Emerging functions of myelin‐associated proteins during development, neuronal plasticity, and neurodegeneration
TLDR
The discovery of a new group of interacting partners for myelin‐associated receptors and ligands, as well as functional studies within or outside the CNS environment, highlights the potential new physiological roles for these proteins in processes, such as development, neuronal homeostasis, plasticity, and neurodegeneration. Expand
Antibodies to myelin‐associated glycoprotein accelerate preferential motor reinnervation
TLDR
Antibody administration has a generalized effect on sensory regeneration that is unrelated to the behavior of motoneurons in the same nerve, and blocking access to MAG in the distal nerve stump thus accelerated and enhanced PMR. Expand
Tissue sparing and functional recovery following experimental traumatic brain injury is provided by treatment with an anti‐myelin‐associated glycoprotein antibody
TLDR
Results indicate that MAG may contribute to the pathophysiology of experimental TBI and treatment strategies that target MAG may be suitable for further evaluation. Expand
Pharmacokinetic aspects of biotechnology products.
TLDR
Extensive use of pharmacokinetic and exposure/response concepts in all phases of drug development has in the past been identified as a crucial factor for the success of a scientifically driven, evidence-based, and thus accelerated drug development process. Expand
The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
TLDR
Three case studies are presented, which outline successful implementation of the translational PK-PD methodology in the rational development of biotherapeutics across various stages of discovery and development. Expand
...
1
2
3
4
...